Cargando…

Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases

Background: Anemia of Chronic Disease (ACD) can negatively influence the clinical course of Inflammatory Bowel Disease (IBD) patients. The aim of this study was to evaluate the effect of Vedolizumab on ACD in IBD. Methods: Clinical data of 75 IBD patients (25 Crohn’s disease (CD) and 50 Ulcerative C...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scarozza, Patrizio, De Cristofaro, Elena, Scucchi, Ludovica, Rocchetti, Irene, Marafini, Irene, Neri, Benedetto, Salvatori, Silvia, Biancone, Livia, Calabrese, Emma, Monteleone, Giovanni
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7408734/ https://www.ncbi.nlm.nih.gov/pubmed/32640680 http://dx.doi.org/10.3390/jcm9072126

Ejemplares similares

Natural History of Ulcerative Colitis with Coexistent Colonic Diverticulosis
por: Marafini, Irene, et al.
Publicado: (2021)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Low frequency of COVID-19 in inflammatory bowel diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Endoscopic Predictors of Neoplastic Lesions in Inflammatory Bowel Diseases Patients Undergoing Chromoendoscopy
por: Lolli, Elisabetta, et al.
Publicado: (2022)

Respiratory Tract Infections in Inflammatory Bowel Disease Patients Taking Vedolizumab: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Marafini, Irene, et al.
Publicado: (2021)

Reversibility of Frail Phenotype in Patients with Inflammatory Bowel Diseases
por: Salvatori, Silvia, et al.
Publicado: (2023)

Frequency and Predictors of Dysplasia in Pseudopolyp-like Colorectal Lesions in Patients with Long-Standing Inflammatory Bowel Disease
por: De Cristofaro, Elena, et al.
Publicado: (2023)

Long-Term Outcomes and Predictive Factors of Hospitalized Patients with Severe Ulcerative Colitis Treated with Intravenous Corticosteroids
por: De Cristofaro, Elena, et al.
Publicado: (2021)

OC.14.1 SARS-COV-2 INFECTION DOES NOT WORSEN THE COURSE OF INFLAMMATORY BOWEL DISEASE IN THE LONG TERM
por: Neri, B., et al.
Publicado: (2023)

Precision Medicine in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2021)

Distinct Profiles of Effector Cytokines Mark the Different Phases of Crohn’s Disease
por: Zorzi, Francesca, et al.
Publicado: (2013)

Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Smoking and colorectal cancer in inflammatory bowel disease: Quantity matters?
por: Marafini, Irene, et al.
Publicado: (2023)

High Frequency of Undiagnosed Psychiatric Disorders in Inflammatory Bowel Diseases
por: Marafini, Irene, et al.
Publicado: (2020)

Long-Term Risk of Colectomy in Patients with Severe Ulcerative Colitis Responding to Intravenous Corticosteroids or Infliximab
por: De Cristofaro, Elena, et al.
Publicado: (2022)

Diagnostic yield of small bowel capsule endoscopy in obscure gastrointestinal bleeding: a real-world prospective study
por: Romeo, Samanta, et al.
Publicado: (2021)

Mucinous and Signet-Ring Cell Colonic Adenocarcinoma in Inflammatory Bowel Disease: A Case–Control Study
por: Neri, Benedetto, et al.
Publicado: (2023)

Metalloproteinases in Inflammatory Bowel Diseases
por: Marônek, Martin, et al.
Publicado: (2021)

Intestinal Taxa Abundance and Diversity in Inflammatory Bowel Disease Patients: An Analysis including Covariates and Confounders
por: Teofani, Adelaide, et al.
Publicado: (2022)

High Smad7 in the early post-operative recurrence of Crohn’s disease
por: Zorzi, Francesca, et al.
Publicado: (2020)

Antisense Oligonucleotide: Basic Concepts and Therapeutic Application in Inflammatory Bowel Disease
por: Di Fusco, Davide, et al.
Publicado: (2019)

Association Between Celiac Disease and Cancer
por: Marafini, Irene, et al.
Publicado: (2020)

A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study
por: Marafini, Irene, et al.
Publicado: (2021)

Interleukin-34 promotes tumorigenic signals for colon cancer cells
por: Franzè, Eleonora, et al.
Publicado: (2021)

Helicobacter pylori and Gastric Cancer: Pathogenetic Mechanisms
por: Salvatori, Silvia, et al.
Publicado: (2023)

Involvement of Smad7 in Inflammatory Diseases of the Gut and Colon Cancer
por: Troncone, Edoardo, et al.
Publicado: (2021)

Long COVID in Inflammatory Bowel Diseases
por: Salvatori, Silvia, et al.
Publicado: (2021)

Predicting Response to Vedolizumab in Inflammatory Bowel Disease
por: Meserve, Joseph, et al.
Publicado: (2020)

Role of Interleukin-34 in Cancer
por: Franzè, Eleonora, et al.
Publicado: (2020)

Oligonucleotides—A Novel Promising Therapeutic Option for IBD
por: Scarozza, Patrizio, et al.
Publicado: (2019)

Long‐term safety of vedolizumab for inflammatory bowel disease
por: Loftus, Edward V., et al.
Publicado: (2020)

Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms
por: Crooks, Benjamin, et al.
Publicado: (2020)

Effect of obesity on vedolizumab response in inflammatory bowel disease
por: Levine, Louis J., et al.
Publicado: (2022)

Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease
por: Lo Presti, Alessandra, et al.
Publicado: (2019)

The impact of COVID-19 pandemic in the colorectal cancer prevention
por: Del Vecchio Blanco, Giovanna, et al.
Publicado: (2020)

Smad7 Antisense Oligonucleotide-Based Therapy in Crohn's Disease: Is it Time to Re-Evaluate?
por: Monteleone, Giovanni, et al.
Publicado: (2022)

Designing biologic selectivity for inflammatory bowel disease – role of vedolizumab
por: Krupka, Niklas, et al.
Publicado: (2014)

Effects of Vedolizumab Therapy on Extraintestinal Manifestations in Inflammatory Bowel Disease
por: Fleisher, Mark, et al.
Publicado: (2018)

A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases
por: Shim, Hang Hock, et al.
Publicado: (2018)

Vedolizumab Is Safe in Elderly Veteran Patients With Inflammatory Bowel Disease
por: Leung, Kenneth, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_72t5gc9js9jbqqpggegs2tutrh